Dulaglutide

Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.

Dulaglutide
Clinical data
Trade namesTrulicity, others
AHFS/Drugs.comMonograph
MedlinePlusa614047
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Subcutaneous
Drug classIncretin mimetics
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • US: WARNINGRx-only
  • EU: Rx-only
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC2646H4044N704O836S18
Molar mass59670.63 g·mol−1

The most common side effects are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.

It is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. GLP-1 is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The Food and Drug Administration (FDA) approved dulaglutide for use in the United States in September 2014. It was approved for use in the European Union in November 2014. In 2021, it was the 70th most commonly prescribed medication in the United States, with more than 9 million prescriptions.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.